Arantis Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 20-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 20-12-2024
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2021)
- Profit -8244.97%
(FY 2021)
- Ebitda -8819.88%
(FY 2021)
- Net Worth -870.78%
(FY 2021)
- Total Assets 340.66%
(FY 2021)
About Arantis Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Palliyalilthodi Salam, Thayyil Rahiman, Noushad Ullattupara, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24299KA2019PTC128064
- Company No.
128064
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Sep 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Arantis Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thayyil Rahiman  | Managing Director | 18-Sep-2019 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Palliyalilthodi Salam | Director | 23-Nov-2020 | Current |
| Noushad Ullattupara | Director | 18-Sep-2019 | Current |
| Thevarthody Shajimon | Director | 18-Sep-2019 | Current |
| Thevar Firoz | Director | 18-Sep-2019 | Current |
Financial Performance of Arantis Pharma.
Arantis Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 8244.97% decrease in profit. The company's net worth observed a substantial decline by a decrease of 870.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arantis Pharma?
In 2021, Arantis Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Kodasseri Extractions Private LimitedActive 2 years 8 months
Palliyalilthodi Salam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arantis Pharma?
Unlock and access historical data on people associated with Arantis Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arantis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arantis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
